THE Therapeutic Goods Administration has released details of an investigation into a rare but serious adverse event of aortic aneurysm/dissection associated with fluoroquinolone antibiotics.
The TGA probe follows a Drug Safety Communication from the US Food and Drug Administration, as well as recommendations from the European Medicines Agency.
Fluoroquinolone antibiotics marketed in Australia include ciprofloxacin, norfloxacin and moxifloxacin, with the TGA saying it had not received any Australian adverse events as reported overseas, but was continuing to monitor the situation closely.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Apr 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Apr 19
